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Dietary Interventions to Modulate the Gut Microbiome—How 
Far Away Are We From Precision Medicine
Francesca De Filippis, PhD,*,† Paola Vitaglione, PhD,*,† Rosario Cuomo, MD,†,‡  
Roberto Berni Canani, PhD,†,§,¶,‖ and Danilo Ercolini, PhD*,†
The importance of the gut microbiome in human health and disease is fully acknowledged. A perturbation in the equilibrium among the different 
microbial populations living in the gut (dysbiosis) has been associated with the development of several types of diseases. Modulation of the gut 
microbiome through dietary intervention is an emerging therapeutic and preventive strategy for many conditions. Nevertheless, interpersonal 
differences in response to therapeutic treatments or dietary regimens are often observed during clinical trials, and recent research has suggested 
that subject-specific features of the gut microbiota may be responsible. In this review, we summarize recent findings in personalized nutrition, 
highlighting how individualized characterization of the microbiome may assist in designing ad hoc tailored dietary intervention for disease treat-
ment and prevention. Moreover, we discuss the limitations and challenges encountered in integrating patient-specific microbial data into clinical 
practice.
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INTRODUCTION
The human body is home to at least 100 trillion (1014) 
microorganisms, most of them inhabiting the human gut. This 
community includes taxa from the 3 domains of life (Bacteria, 
Eukarya, and Archaea) and viruses, whose combined genome 
harbors at least 100 times as many genes as our own genome.1 
The consortium of microbial symbionts that resides in and 
on the human body collectively constitutes our “microbiota”; 
when also considering their pool of genes and the functions 
for which they encode, we refer to it as the “microbiome.” 
The human body can be considered the result of human and 
microbial cells, with our genetic and metabolic potential repre-
senting the arrangement of what comes from our genome and 
microbiome. For these reasons, our gut microbiome has earned 
the appellative of our “other genome.”2
Several studies have focused on the exploration of the 
composition and functionality of the gut microbiome, with an 
emphasis on its bacterial members.3 In healthy adults, 2 bac-
terial phyla dominate, namely Firmicutes and Bacteroidetes, 
which vary in their proportions across the population. 
Proteobacteria, Actinobacteria, and Verrucomicrobia are 
present at lower levels.4 A  categorization of individuals in 3 
groups (“enterotypes”) based on the prevalence of Prevotella, 
Bacteroides, or Ruminococcus in the gut microbiota was pro-
posed in an attempt to simplify the complexity of the gut 
microbiome.5 This classification, although appealing for under-
standing microbial changes in health and disease, has recently 
been criticized, as it may lead to an oversimplified vision of the 
gut microbiome, whereas the existence of smooth gradients in 
the abundance of dominant taxa is now considered to be more 
plausible.6, 7
In this review, we focus on the role of diet in influenc-
ing the composition and functions of the microbiome with 
a particular emphasis on inflammatory bowel disease (IBD) 
and irritable bowel syndrome (IBS). We also discuss the most 
recent evidence for the role of microbiome-targeted dietary 
interventions for promoting host health.
MICROBIAL METABOLITES IN THE GUT
Microbial symbionts interact among themselves and 
with the host, impacting human physiology and health. They 
relate to the host immune system, promoting the maturation 
of immune cells and driving the development of immune 
functions.8, 9 Moreover, gut microbes perform a wide range of 
useful activities, such as fermenting and absorbing undigested 
compounds and synthesizing vitamins.10, 11 They can influence 
host health through the production of beneficial or detrimen-
tal metabolites. Such compounds can be derived from both 
metabolic intermediates of the host and dietary precursors. 
Therefore, diet plays a major role in affecting the metabolic 
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potential of gut microbes. Some specific gut microbiota mem-
bers can produce short-chain fatty acids (SCFAs) from degrad-
ation of complex plant-derived polysaccharides. SCFAs, mainly 
butyrate, propionate, and acetate, exert recognized health-pro-
moting functions, such as anti-inflammatory, anticarcino-
genic, and immune-regulatory functions.12, 13 Nevertheless, 
gut microbiota can also be responsible for the production of 
harmful molecules associated with detrimental effects for the 
host and related to the development of several diseases.12, 13 
A high-protein diet leads to the accumulation of several amino 
acid–derived products in the colon, such as branched-chain 
fatty acids, phenols, p-cresol, and phenylacetic acid, previously 
reported to be associated with pro-inflammatory and carcino-
genic effects.13, 14 Sulfate-reducing bacteria (eg,, Desulfovibrio 
spp.) produce sulfides through the catabolism of sulfur amino 
acids and taurine, which are toxic to colonocytes.13 N-Nitroso 
compounds (NOCs) produced by nitration of amines derived 
from microbial fermentation of proteins may exert carcinogenic 
and mutagenic effects and are correlated with the incidence of 
colorectal cancer.13 In addition, a diet rich in fat attracts more 
bile in the colon, where bile acids may be converted by micro-
bial enzymes into secondary bile acids, mainly deoxycholic and 
lithocholic acids. These can be involved in processes linked to 
colorectal carcinogenesis, such as apoptosis, cell proliferation, 
and DNA damage induction.14
MICROBIOME-RELATED DISORDERS
In recent years, the “1 microbe–1 disease” model has 
been regarded as extremely simplistic and obsolete, whereas 
an increasing number of  studies of  the human microbiome 
have highlighted that many diseases may be a consequence of 
an overall dysbiosis status of  the gut microbiome. Several gut 
commensal microbes may be considered pathobionts; that is, 
they normally inhabit the gut but may act as pathogens and 
cause disease when the normal gut microbial community is 
altered.15 Indeed, perturbation of  the equilibrium in the gut 
microbiome has been linked to the development of  several 
disorders. As they are extensively reviewed elsewhere,16–18 we 
provide a short overview below, with particular emphasis on 
IBD and IBS.
• Obesity: Gut microbiota dysbiosis in obesity is often associ-
ated with increased Firmicutes-to-Bacteroidetes ratio19 and 
persistent inflammation triggered by increased systemic levels 
of lipopolysaccharides arising from Gram-negative bacterial 
cells (metabolic endotoxemia).20, 21 Indeed, the perturbation 
in the gut microbiota composition caused by the consump-
tion of a high-fat diet leads to amplified gut permeability, 
resulting in endotoxemia.21
• Type 2 diabetes and metabolic syndrome: The gut micro-
biome plays an important role in modulating the glycemic 
response, and thus in the development of type 2 diabetes 
(T2D). The gut microbiota of T2D patients is usually 
depleted of fiber-degrading and SCFA-producing bacteria, 
such as Roseburia, Eubacterium, and Faecalibacterium.22
• Cardiovascular diseases: Gut microbiota metabolism of 
choline, phosphatidylcholine, and carnitine leads to trimeth-
ylamine (TMA), which is oxidized in the liver to trimethyl-
amine oxide (TMAO) and seems to be associated with the 
development of atherosclerotic plaques.23, 24
• Immune-mediated adverse food reactions: food allergy and 
celiac disease. These conditions are characterized by an 
abnormal response of the immune system to specific food 
antigens that do not affect the normal population. A genetic 
predisposition is involved in the development of these con-
ditions, but environmental factors acting at least in part on 
gut microbiota could be also implicated.25 Current evidence 
suggests that the gut microbiota and its metabolites, together 
with exposure to dietary factors in early life, critically influ-
ence the immunology of T-cells.26
• Colorectal cancer (CRC): Some bacterial species are suspected 
to be involved in CRC development.27 Although the exact 
mechanisms remain unknown, the production of pro-inflam-
matory or pro-oxidative metabolites and/or toxins, such as 
Bacteroides fragilis BFT toxin,27 and the transformation of 
primary bile acids into secondary bile acids13 may be involved.
• Neurological disorders: Gut microbiota may interact with 
the nervous system through the production of several neu-
ro-active molecules and modulate brain development, func-
tions, human mood, and behavior.28, 29 The complexity of 
these interactions is implied by the term “gut-brain axis.”30 
Moreover, recent evidence suggests that the gut microbiome 
is implicated in the etiology of autism spectrum disorder, 
Parkinson’s, Alzheimer’s, and other neurodegenerative dis-
eases, although the mechanisms underlying these diseases 
remain unclear.31–33
GUT MICROBIOME IN IBD AND IBS
Inflammatory Bowel Diseases
Inflammatory bowel diseases are chronic intestinal dis-
eases characterized by inflammation of the bowel, including 
Crohn’s disease (CD) and ulcerative colitis (UC). UC is man-
ifested exclusively in colonic mucosa, whereas CD affects all 
areas of the gastrointestinal (GI) tract, with features such as 
granulomas and intestinal fibrosis. IBD affects up to 0.5% of 
the population, with the highest incidence in North America 
and Europe.34 The incidence is increasing, especially in devel-
oping countries, with the rate of CD rising faster than that of 
UC.35 This phenomenon seems to be related to changes in the 
Western lifestyle, suggesting that environmental factors, par-
ticularly diet, play a role in the development and progression 
of IBD.36
Furthermore, eating habits also seem to be a key factor 
in the clinical care of patients with IBD. Indeed, acute CD 
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treatment with an elemental diet resulted in a remission com-
parable to treatment with corticosteroids.37 As dietary and 
bacterial antigens are the most common types of luminal anti-
gen, it is reasonable to suppose that dietary factors may play 
an important role in the pathogenesis of IBD, possibly inter-
acting with the gut microbiota and the mucosal immune sys-
tem.38 Gut microbiota dysbiosis was often observed in IBD 
patients, although a causal relationship has not been estab-
lished.39 Some studies reported a decrease of Firmicutes in 
IBD patients, in particular the butyrate-producing Roseburia 
hominis and Faecalibacterium prausnitzii.40, 41 Conversely, 
Proteobacteria, particularly Escherichia coli,40, 42 are com-
monly increased in patients with IBD, whereas the implication 
of some pathogenic bacteria, such as Mycobacterium avium 
paratuberculosis (MAP), adherent invasive Escherichia coli 
(AIEC), Clostridium difficile, Campylobacter, and Salmonella, 
is still controversial.39 In addition, CD patients also showed a 
higher proportion of fungi compared with bacteria, with an 
increased Basidiomycota:Ascomycota ratio, a decreased propor-
tion of Saccharomyces cerevisiae, and an increased abundance 
of Candida albicans.43, 44 However, whether the dysbiosis has a 
causative role in the onset of the inflammation that drives IBD 
development or inflammation arises independently and leads to 
dysbiosis is a matter of ongoing debate.39, 45
Irritable Bowel Syndrome
IBS is a chronic disorder characterized by abdominal pain 
related to defecation or changes in bowel habits.46 Several anal-
yses reported a global prevalence of 14% among females and 
9% among males.47 IBS is commonly categorized into subtypes 
according to the predominant bowel habit: diarrhea-predomi-
nant, constipation-predominant, or mixed/alternating.46 Several 
factors seem to be involved in the development of IBS: visceral 
hypersensitivity, altered brain-gut signaling, immune dysreg-
ulation, psychosocial factors, and microbiota modification.48 
However, most IBS patients report symptoms being triggered 
by specific foods; this causes them to limit or exclude these food 
items, with consequent changes in dietary habits for the manage-
ment of IBS.49 IBS patients often show an increase in Firmicutes, 
particularly unclassified Clostridium cluster IV and XIV, known 
SCFA producers.50 Abnormal levels of butyrate can promote vis-
ceral hypersensitivity and atypical intestinal contractions, which 
are the primary clinical manifestations of IBS.50, 51 Moreover, 
higher levels of mucin-degrading bacteria, such as Ruminococcus 
torques and Akkermansia muciniphila, were found. These spe-
cies can degrade the intestinal mucus barrier and therefore may 
explain the gut inflammatory status in these subjects.50
Microbiome and diet
The gut microbiome may be influenced by several factors, 
among which diet may be considered the most important. The 
long-term habitual diet seems to be the primary factor influ-
encing the gut microbiota. Several recent studies focused on 
the co-evolution between humans and their gut microbiota to 
understand to what extent the Westernization of diet and life-
style have impacted our microbial symbionts and how this has 
affected human health. To this end, it is fundamental to study 
rural and traditional African or South American populations, 
whose lifestyles likely resemble those of Paleolithic or Neolithic 
humans.14, 52–54 Consistent differences in the gut microbiome have 
been found. Westernization induced a loss of microbial diver-
sity and the disappearance of specific taxa, with consequent 
reduction in the capability to degrade complex polysaccharides 
and to produce beneficial metabolites from fiber utilization.55 
Agrarian populations around the world, habitually consuming 
a diet rich in fruit, vegetables, and fibrous tubers and lacking 
in animal products, often show an enrichment in fiber-degrad-
ing bacteria, such as Prevotella, Lachnospira, Treponema, and 
Xylanibacter.14, 52, 54 These changes in gut microbiota compos-
ition are reflected in its functionality. Indeed, agrarians also 
showed a different metabolome compared with Western sub-
jects, with higher levels of beneficial metabolites of microbial 
origin, for example, SCFA.14, 52, 54 Consistently, the consumption 
of a diet rich in fiber in Western subjects (vegetarian/vegan or 
Mediterranean-style diet) promotes higher levels of Prevotella 
and Lachnospira in the gut microbiota, boosting the production 
of beneficial SCFA.56 Nevertheless, studies also highlighted the 
possibility of inducing changes in the gut microbiome through 
a dietary intervention, although these changes are often tran-
sitory, and the gut microbiota tends to revert to the original 
condition.57 The possibility of modulation of gut microbiota 
composition and activity through ad hoc dietary interventions 
is not only fascinating but also a promising research avenue in 
the prevention and treatment of disease.
DIET, GUT MICROBIOTA, AND IBD-IBS 
TREATMENT
Several studies confirmed an association between high 
animal protein and fat intake and increased risk of develop-
ing IBD, both in children and in adults,45, 58 whereas a diet rich 
in olive oil, fish, vegetables, fruits, grains, and nuts has been 
inversely associated with CD in children.59 Moreover, several 
recent studies showed a protective role of breastfeeding against 
the risk of IBD in pediatric patients, although the mechanism 
is largely unclear.60
Based on the dietary recommendations of the National 
Institute for Health and Care Excellence (NICE) and the 
British Dietetic Association,61, 62 the “traditional” IBS diet is 
based on “healthy eating,” reducing fats, caffeine, and excessive 
fiber intake, and avoiding soft drinks and gas-producing foods. 
Furthermore, patients are advised to eat slowly and to chew 
meticulously.61, 62
Several dietary therapies have been proposed for the 
treatment of IBD/IBS patients or symptom relief; these have 
been extensively and recently reviewed.45, 63 However, their effi-
cacy is still controversial, and little is known about the effects 
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of these dietary treatments on the gut microbiome and thus on 
human health.
Specific Carbohydrate Diet
SCD is based on the restriction of  complex carbohy-
drates and the exclusion of  refined sugars from the diet, based 
on the rationale that the sugars and complex carbohydrates are 
badly absorbed and could promote intestinal inflammation.64 
SCD may contain almond, nut, and coconut flours and exclude 
grains (wheat, rice, corn); most dairy products are avoided, 
except for homemade yogurt fermented for 24 hours to deplete 
lactose. Two retrospective studies that assessed SCD as the sole 
method of treatment in CD children showed that the use of 
SCD for 5 to 30 months had positive effects on inflammatory 
markers and clinical presentation of  the disease. The direct 
reason for the improvement was not known, but modification 
of  the intestinal microbiome was proposed as one of  the rea-
sons.65, 66
Exclusive Enteral Nutrition
Exclusive enteral nutrition (EEN), is likely to have sub-
stantial effects on gut microbiota, in part due to carbohydrate 
composition. EEN therapy with elemental, semi-elemental, 
or polymeric formula diets has been widely studied; it is the 
only dietary intervention that induced remission of Crohn’s 
disease and is therefore the firstline therapy in many parts of 
the world. In addition to reducing symptoms, EEN has been 
associated with mucosal healing, which may be a superior pre-
dictor of long-term outcome.67 The results about the effect of 
EEN on gut microbiota are still preliminary and conflicting. 
Lewis and coworkers44 showed that EEN induces changes in the 
gut microbiome of CD children, but these changes did not lead 
to a microbiome resembling that of healthy controls, whereas 
Shiga and collaborators68 reported a reduction of Bacteroides 
fragilis group, commonly found in inflammatory lesions of 
CD patients. Markers commonly associated with health, such 
as microbial diversity or abundance of butyrate-producing 
microbes (eg,, Faecalibacterium prausnitzii) and butyrate levels 
were decreased during EEN intervention.69, 70 Another inter-
esting observation was the higher efficacy of EEN in ileal CD 
compared with colonic CD or UC.71 However, identifying the 
exact role of the diet is hampered by interindividual variabil-
ity in the microbial community and response to intervention. 
The role of specific bacteria in disease improvement is yet to be 
confirmed, as conflicting data have been reported on the protec-
tive effect of Faecalibacterium prausnitzii and other microbes in 
pediatric patients.72, 73
Low-FODMAPs Diet
A recent dietary strategy proposed for IBD/IBS man-
agement is the low–fermentable oligo-, di- and monosaccha-
rides and polyols (FODMAPs) diet.45, 63, 74 Diets rich in highly 
fermentable but poorly absorbed short-chain carbohydrates 
and polyols are hypothesized to trigger symptoms in patients 
with IBS.75 The digestibility of carbohydrates varies according 
to the absence, or reduced production, of hydrolase enzymes 
needed for their digestion. When these sugars arrive undigested 
in the colon, they cause an osmotic effect that attracts water 
in the small intestine. Moreover, they can be fermented by the 
colonic microbiota, with accumulation of gases, including 
hydrogen and methane. Both water and gas increase intestinal 
volume, which, together with visceral hypersensitivity, causes 
pain. However, other mechanisms are evoked in the injurious 
effect of FODMAPs. Indeed, these molecules seem to increase 
GI motility, which further reduces absorption and increases 
potential colonic fermentation.76 A  low-FODMAPs diet can 
reduce the production of SCFAs as a result of limited avail-
ability of fermentable substrates and decreased levels of taxa 
involved in SCFA production.77 Because SCFAs induce vis-
ceral hypersensitivity, the decrease in their luminal levels may 
represent another mechanism accounting for the efficacy of a 
low-FODMAPs diet.78, 79
FODMAPs might be considered “fast food” for bac-
teria and can lead to the expansion of specific bacterial pop-
ulations in the distal small intestine. This bacterial overgrowth 
is similar in patients with IBS, celiac disease, and Crohn’s dis-
ease.80, 81 Bacterial overgrowth in the small intestine has been 
associated with increased small intestinal permeability. Fructo-
oligosaccharides increase intestinal permeability also in the 
colon, and in rats experimentally infected with Salmonella, 
FODMAPs predispose to severe colitis, in comparison with a 
mild colonic inflammation occurring in controls.82 It is worth 
emphasizing that rapidly fermentable fiber compromises the 
proximal large bowel, whereas concurrent ingestion of slowly 
fermentable or nonfermentable substrates decreases the rate 
of fermentation, shifting it more distally in the colon.83 This 
mechanism could also be explained by the different localiza-
tion of the inflammatory processes. Hence, the pathogenic 
hypothesis of inflammation development in IBD considers an 
initial increase in fermentable sugar (eg,, FODMAPs) con-
sumption, which determines bacterial overgrowth and a con-
sequent increase in intestinal permeability. Bacterial or antigen 
translocation triggers an immunologic response and acti-
vation of the inflammatory cascade. Data from the literature 
suggest that a low-FODMAPs diet decreases gut symptoms in 
IBD and IBS patients, also promoting a shift in the gut micro-
biota.45, 48, 83 In a single-blind randomized clinical trial (RCT) in 
patients with IBS, a low-FODMAPs diet promoted an increased 
richness of Actinobacteria, Firmicutes, and Clostridiales 
and a decreased abundance of bifidobacteria compared with 
a high-FODMAPs diet.83 In the same study, a higher abun-
dance of the hydrogen-consuming genus Adlercreutzia was 
found in the low-FODMAPs group, possibly contributing 
to a reduction of symptoms, due to the consumption of the 
accumulated gas in the intestine.83 Consistently, another study 
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reported a decreased proportion of bifidobacteria in patients 
with IBS after a low-FODMAPs diet.75 In patients with Crohn’s 
disease, FODMAPs intake is also associated with changes in 
fecal microbiota. Indeed, an Australian diet rich in FODMAPs 
boosted the levels of butyrate-producing Clostridium cluster 
XIVa and mucus-associated Akkermansia muciniphila. This diet 
seems to increase IBS-like symptoms.75 Moreover, Chumpitazi 
and coworkers84 observed that children with IBS showing a 
positive response to a 2-day low-FODMAP intervention had 
higher baseline abundance of Sporobacter and Subdoligranum 
and decreased Bacteroides compared with nonresponders. 
Modulation of FODMAPs intake seems to be a promising 
strategy for treating abdominal symptoms in patients with 
IBD and IBS. However, potential hazards do exist, such as the 
decrease in bifidobacteria and other fiber-degrading bacteria, 
recognized for their health-promoting benefits, along with the 
consequent reduction of beneficial SCFA levels.85 Therefore, 
the routine utilization of this strategy for IBD/IBS treatment 
should be applied carefully, ideally coupled with gut microbiota 
monitoring, to avoid induction of dysbiosis. Considering these 
factors, the addition of probiotics during a low-FODMAPs 
diet may be a possible solution to optimize clinical manage-
ment and prevent the detrimental effects of a low-FODMAPs 
diet on the gut microbiome.
PERSONALIZED NUTRITION AND GUT 
MICROBIOME
Key Factors in a Dietary Intervention for 
Personalized Clinical Applications
Clinical interventions cannot be based solely on clinical 
experience and observational studies but need to be based on 
evidence provided by RCTs.86, 87 Despite their cost and labor-in-
tensiveness, RCTs are the most valid research design for evi-
dence-based medicine; nutrition is a field in need of better 
clinical research.88 This gap is the focus of the European Clinical 
Research Infrastructures Network (ECRIN) Integrating 
Activity (IA; http://www.ecrin.org/activities/projects), which 
has identified barriers to good clinical research and offered 
solutions to improve evidence-based clinical practice.89–91
Critical Factors in Nutritional Studies
The main difficulty in identifying a causal relationship 
between the consumption of a specific diet, food, or nutrient 
and a health outcome is the coexistence of several factors that 
interact and may possibly lead to biased results if  not appropri-
ately considered. These factors include population characteris-
tics and lifestyle; the bioavailability of the nutrient (which is in 
turn influenced by aspects related to the technology of produc-
tion and method of consumption); the timing, frequency, and 
duration of nutrient exposition; and contextual factors (eg,, 
foods, supplements, medications, and diseases that can aid or 
hinder absorption).
Therefore, to demonstrate a causal relationship of a 
specific nutrient/diet on a health outcome, a multidisciplinary 
and multisystem approach is necessary. This approach requires 
simultaneously considering nutrition, genetics, the microbi-
ome, and environment (exposome) in the implementation of 
nutritional intervention studies, as was recently suggested in 
an epidemiological study.92 This strategy could have multiple 
spillover effects, including being able to explain and overcome 
the discrepancies present in the scientific literature for the effi-
cacy of some nutrients/diets, achieving stronger evidence and 
consensus in the scientific community, and producing practical 
and valuable applications in the fields of personalized nutri-
tion, preventive and precision medicine, and functional food 
development.
Critical factors in the implementation of nutritional 
intervention studies and opportunities beyond nutrition are 
summarized in Figure 1; a systems-based approach could work 
in nutritional interventions and specifically in nutritional RCTs. 
The scheme highlights 4 critical points in RCTs, namely, study 
design, subjects, biomarkers, and data analysis. Each of them 
must be carefully considered during the implementation of the 
trial tailored to nutrient/diet and targeted health outcomes.
Study design
The type and form of nutrient, whether provided as a 
supplement or included in a food, can considerably influence 
the study design. Indeed, in the case of a supplement, a placebo 
(a pill/powder/tablet/liquid similar to the experimental one but 
without the putative bioactive compound) can be provided and 
a double-blind trial (which is the gold standard design because 
it guarantees the blinding of both subjects and investigators) 
can be performed. Conversely, in the case of a nutrient included 
in a food or a diet, finding the correct control intervention can 
be a remarkably critical point. This affects the study design and 
the data analysis. In the frame of study design, blinding can be 
compromised because, without a placebo, a double-blind trial 
is impossible and the dose/frequency of food consumption and 
the duration of the intervention must be carefully considered 
in view of the bioavailability of the putative bioactive nutrient 
in the food.
Sample size calculation and study power
Power analysis for sample size calculation is usually car-
ried out based on variations in clinical parameters. Calculating 
sample size based on microbiome features, although possible, 
may often be impracticable, as we do not know the effect that 
a specific dietary intervention may have on the complex con-
sortium of gut microorganisms, with diverse taxa responding 
in different ways to the treatment. Focusing on the abundance 
of only a few taxa may be also unsuccessful. Moreover, due 
to the high interpersonal variability in gut microbiome com-
position, the resulting sample size would be excessively high, 
making the study unfeasible. As many of the studies found 
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in the literature are based on a small number of subjects, the 
effects on the microbiome may be hidden by high interpersonal 
variability, and this may explain the often inconclusive results 
obtained in terms of the modulatory effect on the microbiome. 
Tools for sample size calculation in microbiome studies have 
been recently developed; however, their use remains limited.93, 94
Subjects selection
Subjects’ characteristics, such as age, nutritional and 
health status, genetics, the gut microbiome, and behavioral 
and lifestyle factors may enormously influence the metabolic 
response and the health effect of  a nutrient/diet. Thus, having 
clear and strict inclusion and exclusion criteria in RCTs may 
allow investigators to have interventions with smaller numbers 
of  subjects while maintaining a good power of  the study to 
reduce costs and time of  the trials and to enhance the probabil-
ity of  clarifying the mechanisms underlying the health effect. 
The latter aspect is also influenced by biomarkers of  effective-
ness monitored during the study. In the case of  clinical trials 
involving patients, the evaluation of  markers of  the specific 
FIGURE 1. Critical factors in the implementation of nutritional intervention studies and opportunities beyond nutrition. Randomized clinical trials 
represent the gold standard to achieve evidence-based medicine. Effective nutritional RCTs must be tailored to the specific nutrient/diet and health 
outcome of interest. The scientific validity of evidence achieved by RCTs depends on the critical management of 4 main points, namely study design, 
subjects, biomarkers of responsiveness, and data analysis. Numerous factors coexist and interact between each other to influence the effect of nutri-
ent/diet on a specific health outcome. These factors mainly include population characteristics and lifestyle, dose and bioavailability of the nutrient, 
timing, frequency, and duration of nutrient exposition, and contextual factors. Due to the involvement of the gut microbiome in the fine interplay 
between nutrient/diet-subjects-health, its consideration at multiple steps of RCTs (ie, at selection of subjects, biomarkers, and data analysis) may 
be crucial. The proper consideration and management of all the critical factors allows scientists to achieve evidence that can find application in the 
fields of personalized nutrition, preventive and precision medicine, and functional food development.
Downloaded from https://academic.oup.com/ibdjournal/advance-article-abstract/doi/10.1093/ibd/izy080/4970097
by University of Durham user
on 13 April 2018
Inflamm Bowel Dis • Volume 00, Number 00, Month 2018 
7
Dietary Interventions to Modulate the Gut Microbiome
disease under investigation is necessary. In addition, other bio-
markers that are usually considered in subjects at a predisease 
stage may also be monitored. These include inflammatory, 
nutritional, and metabolic biomarkers, and gut microbiota 
composition. Most belong to the fine net of  signaling medi-
ators involving the metabolic, neuroendocrine, and immune 
systems; orchestrating the response to a nutrient/diet; and the 
organ-by-organ communication and homeostasis processes 
within the body.11, 95, 96 Finally, to monitor changes in the gut 
microbiome, antibiotic or probiotic assumption should be con-
sidered as an exclusion criterion, or, when this is not possible 
(eg, when intervention is addressed to patients), investigators 
should consider it a possible confounding factor.
Biomarker evaluation and data analysis
In the frame of data analysis, the evaluation of individ-
ual compliance is the critical factor. Indeed, in the presence of 
a supplement/placebo, the count of not-consumed doses may 
be sufficient, whereas in the case of a food/diet-based interven-
tion, the evaluation of individual dietary intake (through food 
frequency questionnaires, 24-hour recall, weighed food record, 
etc.) or biomarkers of food/diet intake in biological fluids 
(through metabolomics analysis) is necessary. Although univo-
cal biomarkers of intake have not been recognized for many 
foods, metabolomics of biological fluids is inestimably valuable 
for RCTs because it can show the impact of the intervention on 
individual nutrient metabolism in relation to the subjects’ char-
acteristics being considered in the study. This aspect is funda-
mental in targeted nutrition and medicine. Mounting evidence 
shows that through metabotyping—that is, grouping metabol-
ically similar individuals—personalized nutritional and phar-
macological strategies may be achieved.92, 97 On the other hand, 
the approach of grouping similar individuals for some features 
can be applied in RCTs both at the stage of subject selection 
and during data analysis.
Overall, a multisystem approach in clinical trials is the 
most valuable way to achieve evidence-based medicine and to 
reduce the gap currently existing between research and clin-
ical findings with possible practical applications in the fields of 
personalized nutrition, preventive and precision medicine, and 
functional food development.
Dietary Interventions for the Modulation of the 
Gut Microbiome
Several studies highlighted the effect of a dietary inter-
vention on the gut microbiome, focusing on the addition of a 
specific supplement to the diet (mainly different types of diet-
ary fiber) or administering diets enriched in carbohydrates, pro-
teins, or fats (Table 1). Adding prebiotic fiber to the diet may 
lead to the enrichment of fiber-degrading bacteria in the gut 
and improved metabolic health, but results reported in the cur-
rent literature have been conflicting. Studies are often limited to 
a small number of subjects (20 per treatment group or fewer in 
many cases) (Table 1).
Moreover, comparison of results across studies is not 
always possible, as many confounding factors exist, making 
it necessary to have standardized procedures for sample col-
lection, storage, and subsequent analyses,115 such as those 
proposed by the International Human Microbiome Standard 
Consortium (http://www.microbiome-standards.org).
Although host genomics may also be implicated, inter-
subject variation in gut microbiota composition may explain 
the different metabolic responses observed with the same treat-
ment. Interpersonal differences in response to the same type of 
drug have been often observed in therapeutic routines. The gut 
microbiome may be involved in this process through bio-trans-
formation of bioactive compounds contained in administered 
drugs, reducing or sometimes enhancing their effects.10, 116 
Statins, commonly used to reduce plasma low-density lipopro-
tein (LDL) levels, are an example of microbiome-driven person-
alized response to drugs. Indeed, subjects positively responding 
to statin treatment showed increased levels of specific secondary 
bile acids of microbial origin.10 Therefore, the design of thera-
peutic treatments should consider personalized microbiome 
features and their effects on drug metabolism, toxicity, and effi-
cacy. Accordingly, recent studies highlighted that subject-spe-
cific gut microbiome traits cannot be disregarded if  diet must 
be used to beneficially modulate microbiome activities for ther-
apeutic approaches (Fig.  2). Indeed, the gut microbiota may 
be responsible for unpredictable results in intervention studies. 
Features of the gut microbiome before starting the intervention 
(eg, overall microbial diversity or abundance of specific taxa, 
such as Prevotella copri or Akkermansia muciniphila) were pre-
viously suggested to be discriminant factors between subjects 
showing a metabolic improvement (eg, decrease in LDL chol-
esterol, inflammatory markers, or insulin resistance) to a diet-
ary intervention and those who were not beneficially impacted 
(Fig. 2). For example, 3-day consumption of barley kernel fiber 
led to improved glucose metabolism, reducing postprandial gly-
cemic response (PPGR) and insulin, but only in a subset of the 
cohort studied.108 Separating responders from nonresponders, 
the authors observed higher Prevotella copri concentrations in 
responders. Moreover, gavaging mice with live P. copri cells, they 
confirmed the positive effect exerted on glucose metabolism, 
possibly due to a promotion of hepatic glycogen storage.108 In 
contrast, Pedersen and coworkers117 suggested that P. copri may 
be responsible for branched-chain amino acid production and 
induce insulin resistance, demonstrating that the association 
of a whole microbial genus or species with a specific metabolic 
outcome may be an oversimplification.118, 119
Indeed, it must be noted that high variability at the strain 
level exists in the gut microbiome, and in any other complex 
environment, although this point was largely overlooked until 
recently. Every species may be represented by several different 
strains, with intersubject variability.120 Strains belonging to 
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TABLE 1: Main Clinical Trials Assessing the Gut Microbiome and Metabolic Responses After Dietary Intervention
Study
Intervention Population Outcomes
Description No. Description Microbiota Bioclinical Variables
Bennet et al., 
201798
4 weeks of low-FODMAPs 
or traditional IBS
67 IBS patients
BMI 24.0 ± 6.0 kg/m2
17% male
No change in the microbiota 
after traditional IBS diet both 
in responders and nonrespond-
ers; >Bacteroides stercoris, 
Ruminococcus gnavus, Dorea, 
and several Enterobacteriaceae 
at baseline in nonresponders 
compared with responders to 
low-FODMAPs diet
Decrease in IBS symp-
toms Severity score 
≥50 in responders
Candela et al., 
201699
3 weeks of macrobiotic diet 
(Ma-Pi; enriched in fiber, 
hypocaloric) or control diet 
with the same energy intake
40 Type 2 diabetes
BMI 34.3 ± 6.5 kg/m2
50% male
>Akkermansia, Ruminococcus, 
Faecalibacterium, Blautia after 
both the dietary intervention; 
<Collinsella, Streptococcus, and 
>Akkermansia after Ma-Pi com-
pared with control diet
Decrease of postpran-
dial glucose, LDL 
cholesterol, insulin 
resistance, inflamma-
tory markers after 
Ma-Pi diet
Chumpitazi 
et al., 2015100
2 days of low-FODMAPs or 
typical American diet
33 IBS pediatric patients 
(age 7–17 years)
BMI and sex not 
provided
>Bacteroides, Ruminococcaceae, 
Dorea, Faecalibacterium praus-
nitzii at baseline in responders
Decrease in abdominal 
pain and gastroin-
testinal symptoms in 
responders
Costabile et al., 
2008101
3 weeks of supplement with 
48 g of whole grain (WG) 
or wheat bran
31 BMI 25.0 ± 5.0 kg/m2
48% male
>Bifidobacterium, Lactobacillus 
after WG
Increase of phenolic 
acids in WG, no 
changes in blood 
lipids, cholesterol, glu-
cose, insulin
Cotillard et al., 
2013102
6 weeks of hypocaloric, 
high-protein diet
(1200 and 1500 Kcal/d for 
men and women, respec-
tively); 6 weeks of stabi-
lization diet (20% caloric 
increase)
49 BMI 33.2 ± 0.5 kg/m2
16% male
Divided into low (LGC; 
n = 20) and high 
(HGC; n = 29) gene 
count
>diversity in LGC after the dietary 
intervention
Decrease of insulin 
resistance, triglycer-
ides, inflammatory 
markers in HGC after 
intervention
Dao et al., 
2016103
6 weeks of hypocaloric, 
high-protein, low-carbohy-
drate diet enriched in fiber; 
6 weeks of weight mainte-
nance diet
49 BMI 32.5 ± 1.0 kg/m2
17% male
Divided into high 
(HAk; n = 25) and 
low (LAk; n = 24) 
Akkermansia mucin-
iphila abundance
<Akkermansia muciniphila after 
the intervention in HAk but still 
higher than LAk
Higher decrease of LDL 
cholesterol, plasma 
glucose, tryglycerides, 
insulin resistance in 
subjects with higher 
baseline levels of 
Akkermansia (HAk)
Hald et al., 
2016104
4 weeks of Western-style diet 
or high-carbohydrate diet 
(enriched in arabinoxylan 
and resistant starch)
19 BMI 30.0 ± 2.0 kg/m2
Sex not provided
>Bifidobacterium and 
<Bacteroides, Odoribacter, 
Desulfovibrionaceae, 
Ruminococcus (Lachnospiraceae)
-
Haro et al., 
2016105
12 months of Mediterranean- 
style diet (MD; 35 fat— 
22% monounsaturated; 
6% polyunsaturated and 
7% saturated) or low-fat, 
high-carbohydrate diet 
(LFHCD; 28% fat—12% 
monounsaturated; 8% 
polyunsaturated and 8% 
saturated)
20 BMI 32.2 ± 0.5 kg/m2
100% male
>Roseburia, Oscillospira, and 
<Prevotella in MD
>Prevotella, Faecalibacterium 
prausnitzii, and <Roseburia in 
LFHCD
Increase of insulin sensi-
tivity in both MD and 
LFHCD
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Study
Intervention Population Outcomes
Description No. Description Microbiota Bioclinical Variables
Hjorth et al., 
2017106
6 months of ad libitum New 
Nordic Diet (NDD; rich in 
fruit, vegetables, and whole 
grains) or Average Danish 
Diet 
62 BMI 30.0 ± 1.0 kg/m2
33% male
Divided into high 
(n = 28) and low 
(n = 34) Prevotella- 
to-Bacteroides ratio 
groups
- Higher body fat and 
waist circumference 
loss after NDD in 
high Prevotella-to- 
Bacteroides group
Korem et al., 
2017107
1 week of supplement with 
145g/d of sourdough-leav-
ened whole grain bread 
or 110 g/d of industrial 
white bread, separated by 2 
weeks of washout
20 BMI 27.9 ± 4.0 kg/m2
45% male
No effect detected Interpersonal varia-
tion in the glycemic 
response after bread 
consumption is 
dependent on baseline 
microbiome features
Kovatcheva- 
Datchary 
et al., 2015108
3 days of supplement with 
barley kernel bread (BKB) 
or white bread
20 BMI 25 ± 3.0 kg/m2
10% male
Divided into responders 
(n = 10) and non-
responders (n = 10) 
based on metabolic 
response to BKB 
intervention
>Prevotella in responders com-
pared with nonresponders;
>Prevotella copri and methano-
genic Archaea after BKB inter-
vention only in responders
Decrease of postpran-
dial blood glucose 
and insulin after BKB 
intervention only in 
responders
Louis et al., 
2016109
3 months of very low-calorie 
diet (800 Kcal/d, enriched 
in inulin); 9 months of 
gradual reintroduction of a 
normal diet; 12 months of 
weight maintenance diet
16 BMI 43.0 ± 7.0 kg/m2
44% male
Persistent success group 
(PS; >10% weight 
loss after 24 months, 
n = 9); no persistent 
success (NS; <10% 
weight loss after 
24 months, n = 7)
Different microbiota at baseline in 
PS and NS groups
>Akkermansia, Alistipes, 
Clostridium leptum, and 
<Bacteroides in PS at baseline
Only Akkermansia stable after 
2 years
Decrease of insulin 
resistance
Pedersen et al., 
2016110
12 weeks of supplement with 
galacto-oligosaccharyde 
mixture or placebo 
29 Type 2 diabetes
BMI 28.0 ± 6.5 kg/m2
100% male
No effect detected No effect detected
Roager et al., 
2017111
8 weeks of intervention with 
a whole grain–enriched diet 
and 8 weeks of intervention 
with a refined grain diet, 
separated by a washout 
period of 6 weeks
60 High risk of metabolic 
syndrome
BMI 25–35 kg/m2
Sex not provided
>Faecalibacterium prausnitzii and 
Prevotella copri after whole grain 
diet
Bacteroides thetaiotaomicron 
increased after refined grain diet
Decrease of inflamma-
tory markers
Weight loss
Vanegas et al., 
2017112
2 weeks of run-in consum-
ing a Western-style diet, 
followed by 6 weeks of 
weight-maintaining diet 
supplemented with 8 g/1000 
Kcal of refined grains (RG) 
or 16 g/1000 Kcal WG
81 BMI 26 ± 0.47 kg/m2
63% and 59% male 
in RG and WG, 
respectively
>Lachnospira, Roseburia, and 
<Enterobacteriaceae after WG 
intervention compared with RG
No effect on inflam-
matory and immune 
markers
Vitaglione et al., 
2015113
8 weeks of WG (70 g/d) or 
refined grain (RF; 60 g/d)
68 BMI 30 ± 0.9 kg/m2
31% and 37% male in 
WG and RF groups, 
respectively
>Prevotella and
<Dialister, Bifidobacterium, 
Blautia, Collinsella in WG
Decrease of inflamma-
tory markers, increase 
of phenolic acids
Walker et al., 
2011114
1 week of weight mainte-
nance, 3 weeks of non-
starch polysaccharides, 
followed by 3 weeks of 
resistant starch (RS) and 
3 weeks of high-protein, 
hypocaloric diet
14 BMI 39.4 ± 1.5 kg/m2
100% male
>Eubacterium rectale, 
Ruminococcus bromii in RS
-
TABLE 1: Continued
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the same species may harbor a significantly different genomic 
repertoire and may respond in different ways to dietary com-
ponents,118, 119 making it even more difficult to demonstrate a 
causative role of diet in the modulation of the gut microbiome.
Different subjects may have distinctive metabolic 
responses to the same food. Subjects with a higher Prevotella-to-
Bacteroides ratio (P/B) had higher weight loss after consuming 
a 6-month high-fiber diet compared with the low P/B group,106 
whereas Dao and coworkers103 observed that obese subjects 
with higher levels of Akkermansia muciniphila showed better 
metabolic outcomes (lower insulin resistance, LDL choles-
terol) compared with those with a lower baseline concentration 
of this microbe, when treated with a hypocaloric, high-pro-
tein and -fiber diet (Table 1). In addition, it was demonstrated 
that a meal cannot be considered “good” for everybody.121 The 
authors integrated gut microbiota features with anthropomet-
ric and metabolic measures, dietary habits, physical activity, 
and lifestyle in a machine-learning algorithm that accurately 
predicted personalized PPGR to real-life meals. This predictive 
strategy was then used to personalize dietary intervention and 
modify postprandial glucose response. They demonstrated that 
baseline microbiota composition may be implicated in the sub-
ject-specific response to a dietary intervention and that consid-
ering these differences may help in designing tailored meals for 
improving metabolic health.121 Accordingly, the same authors 
suggested that the glycemic index of a food alone cannot always 
be useful in predicting the glycemic response. They found the 
PPGR to white or whole grain bread to be person-specific and 
used microbiome composition to predict which type of bread 
resulted in the best glycemic response.107 Indeed, subject-spe-
cific signatures in the gut microbiome may be responsible for 
weight regain after a dietary intervention, and the extent of 
such regain may be predicted by integrating gut microbiome 
features in a machine-learning algorithm.122
Although many studies focused on the administra-
tion of specific food supplements, the habitual consump-
tion of a healthy and diverse diet, such as that based on the 
Mediterranean model, is recognized to shape the gut micro-
biome and to promote the production of beneficial metabo-
lites.56 Although with a limited number of subjects, Haro and 
coworkers105 demonstrated that dietary treatment for 1  year 
with a Mediterranean-style diet improved insulin sensitivity 
and increased the abundance of SCFA-producing microbes 
(Table 1). These examples suggest that following a healthy and 
diverse dietary pattern and lifestyle can contribute to main-
taining a “healthy” microbiome without necessarily adopting 
microbiome-targeted nutritional interventions.
Most of the studies available on targeted dietary modu-
lation of the gut microbiome have focused on metabolic disor-
ders (Table 1). However, the same approach may be useful for 
FIGURE 2. Subject-specific gut microbiota features may affect the response to a dietary intervention. The metabolic response to a dietary interven-
tion is person-specific, and the same type of food or dietary pattern may produce different effects. Dividing responders and nonresponders, recent 
studies showed differences in gut microbiota composition and that this may be the cause of the personalized response to a dietary intervention, 
thus highlighting the necessity of personally tailored nutrition based on gut microbiota composition for therapeutic and preventive purposes.
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other pathologies, such as IBD and IBS. Indeed, Bennet and 
coworkers98 found different baseline microbiota composition in 
adult IBS patients responding or not to a low-FODMAP diet 
(ie, showing a decrease of the IBS Symptoms Severity Score). 
Nonresponders had higher baseline abundance of several taxa, 
eg, Bacteroides stercoris, Pseudomonas, Acinetobacter, and 
Ruminococcus gnavus, compared with responders. Baseline 
microbiota features were implemented in a Random Forest 
model, which was used to predict the probability of a posi-
tive response to the dietary treatment. This pioneer study first 
highlighted the possibility to choose the most appropriate diet-
ary treatment for IBS patients, based on their gut microbiota 
composition.
Based on these observations, it is plausible that in the near 
future, subjects will be stratified based on their gut microbiome 
features and study enrollment will be performed considering 
their baseline microbiome. As we know some associations of 
specific microbial genera/species with diet and/or diseases, we 
can speculate on the possibility of stratifying subjects accord-
ing to the abundance of microbial taxa recognized for certain 
functional activities (eg, fiber-degrading) or for the production 
of beneficial/detrimental metabolites. Although considering 
the microbiota as a stratification factor for subject enrollment is 
promising, several issues arise, including increased enrollment 
costs and the intrasubject variability of the gut microbiota even 
in a short time frame. The possibility of stratifying the study 
population a posteriori for the similarity of the microbiome 
or microbial metabolite profile during data analysis is also an 
alternative. Nevertheless, it must be pointed out that these sec-
ondary analyses do not preserve the benefits of randomization. 
In addition, such stratifications are less likely to be reproduci-
ble due to the risk of chance findings related to multiple test-
ing. Despite the abovementioned limitations, modulating and 
manipulating the gut microbiome with a personally designed 
dietary intervention to induce changes in its composition and 
functions is surely a promising application for both therapeutic 
and preventive clinical strategies.
CONCLUSIONS
Microbiome-targeted dietary interventions constitute a 
powerful and tantalizing tool for the prevention and treatment 
of different diseases. We are still quite far from microbiome-tar-
geted precision medicine, but we are surely on the right scien-
tific path to developing an exhaustive set of tools and clinical 
knowledge to fill the current gaps. Personalized nutrition based 
on microbiome features is currently being attempted, although 
its real impact and benefits suffer from the aforementioned lim-
itations. Most of the studies available are observational, and 
controlled clinical trials targeting the microbiome are still too 
scarce to draw definitive conclusions or to propose a stand-
ardized protocol for modulating the gut microbiome through 
the diet for therapeutic purposes. Future intervention studies 
will surely provide new knowledge and will help in overcoming 
the current issues associated with such types of interventions. 
Indeed, interindividual variations in gut microbiome compos-
ition and functions, along with the need to study the effect of 
dietary changes on microbiome functions at the strain level, 
make the use of such interventions still only exploratory in clin-
ical practice.
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